• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Treace Medical Named First Medical Device Partner and Official Foot and Ankle Solution Partner of the PPA Tour

    4/24/24 7:00:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care
    Get the next $TMCI alert in real time by email

    DALLAS and PONTE VEDRA, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- The Professional Pickleball Association (PPA) Tour and Treace Medical Concepts, Inc. (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Treace Medical has been named the first Medical Device Partner and Official Foot and Ankle Solution Partner for the PPA Tour.

    Treace was the first medical device company to become a PPA sponsor at last year's National Championships. Beginning with the Fanatics Sportsbook North Carolina Cup presented by CIBC earlier this month, Treace Medical's partnership includes dedicated space and fan activations at six PPA Tour events with thousands of fans and players at stops across the country. Additionally, official player challenges of calls during a match will now be known as the "Bunion Challenge." The partnership will also include signage, clinics and pro experiences.

    "We're proud and excited to welcome Treace Medical to the PPA Tour," said PPA Tour Founder and CEO Connor Pardoe. "Footwork is a key component of playing pickleball at the highest level, and to be aligned with the experts and leaders in the field of bunion and related midfoot deformities will help players of all skill levels to perform at their best."

    Lapiplasty 3D Bunion Correction

    As the Official Foot and Ankle Solution Partner for the PPA Tour, Treace is uniquely positioned to drive greater awareness of the challenges posed by bunions, which affect over 67 million Americans,1 and educate patients on its pioneering Lapiplasty® procedure, the #1 most commonly used 3D bunion correction procedure by U.S. surgeons.2  

    "As the fastest growing company in the foot and ankle market,3 we are thrilled to partner with the PPA Tour to support the fastest growing sport in America," said John T. Treace, CEO and Founder of Treace. "Since our first surgical cases in 2015, over 100,000 patients have chosen the Lapiplasty® procedure to address painful, lifestyle-limiting bunions with the goal to get back on their feet in sneakers at 6-8 weeks.4,5 We look forward to reaching even more people through our partnership with the PPA Tour and raising awareness of the impact that effective bunion treatment can have on the quality of life for patients."

    The Carvana PPA Tour is the premier pickleball tour, showcasing the world's best players week in and week out all across the country. Top players like World No.1s Ben Johns and Anna Leigh Waters and tennis champs-turned-pickleball-pros Jack Sock and Genie Bouchard will be fighting for gold in singles, doubles and mixed doubles at this year's prestigious events on the PPA Tour calendar.

    Treace Medical will make their next stop on the PPA Tour at the Veolia Sacramento Open, June 5-9. For tickets and to register to compete, visit ppatour.com.

    About Carvana PPA Tour

    Founded in 2019, the Carvana PPA Tour is where pickleball's top athletes go head-to-head to determine the best male and female players in the world. The Carvana PPA Tour organizes and conducts tournaments at world-class facilities across the country, establishes player rankings, and showcases the world's best pickleball week in and week out. Inviting amateur players to also compete and "play where the pros play," the Carvana PPA Tour offers divisions for every age group and skill level. Characterized by a uniquely festive and fun atmosphere, Carvana PPA Tour events deliver unparalleled experiences for fans on-site, including pro player meet-and-greets, clinics, food, beverages, live entertainment, giveaways, games, shopping, and VIP upgrades. For more information, go to www.ppatour.com, and follow us on social: Twitter, Instagram, YouTube, Facebook, LinkedIn.

    About Treace Medical Concepts

    Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com and connect with us on LinkedIn, Twitter, Facebook and Instagram.

    1 Nix S, et al. J Foot Ankle Res. 2010;3:21.

    2 AOFAS Member Survey August 2023.

    3 TMC estimate based on other publicly-traded peers participating in the foot and ankle market.

    4 TMC Data on File.

    5 Individual results and recovery times may vary. Ray J, et al. Foot Ankle Int. 2019 Aug;40(8):955-960.

    Media Contact:

    Jeff Watson, VP of Communications, PPA Tour [email protected], 817-944-2298

    Treace Medical Concepts, Inc.

    Julie Dewey, Chief Communications & IR Officer, [email protected], 209-613-6945

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7feb977a-0832-4004-88db-1d47a24f9cec.



    Primary Logo

    Get the next $TMCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TMCI

    DatePrice TargetRatingAnalyst
    11/7/2025$5.00Neutral → Underweight
    Analyst
    11/7/2025Buy → Neutral
    BTIG Research
    2/4/2025$16.00Neutral → Buy
    BTIG Research
    12/31/2024$14.50Buy
    Lake Street
    12/17/2024$8.00Neutral
    Analyst
    5/16/2024$16.00 → $6.50Buy → Neutral
    UBS
    5/8/2024$15.00 → $5.50Overweight → Equal-Weight
    Morgan Stanley
    5/8/2024$17.00 → $7.00Buy → Hold
    Truist
    More analyst ratings

    $TMCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

    PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025. Recent Highlights Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% compared to the prior year.Reported fourth quarter 2025 net loss of $(9.4) million and adjusted EBITDA of $6.2 million in the fourth quarter 2025. Reported full-year 2025 net loss of $(59.0) million c

    2/27/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference

    PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™, MTA3D™, and SpeedMTP® clinical studies at the American College of Foot and Ankle Surgeons ("ACFAS") Annual Scientific Conference in Las Vegas, Nevada from February 24-26, 2026. "We are proud to showcase our latest clinical data and innovations at ACFAS, including our next-generation Lapiplasty® instrumentation and fixation technology pla

    2/24/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

    PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask qu

    2/12/26 5:13:32 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Treace Medical Concepts downgraded by Analyst with a new price target

    Analyst downgraded Treace Medical Concepts from Neutral to Underweight and set a new price target of $5.00

    11/7/25 8:29:21 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts downgraded by BTIG Research

    BTIG Research downgraded Treace Medical Concepts from Buy to Neutral

    11/7/25 8:29:10 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts upgraded by BTIG Research with a new price target

    BTIG Research upgraded Treace Medical Concepts from Neutral to Buy and set a new price target of $16.00

    2/4/25 7:10:07 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Scanlan Sean F. exercised 16,875 shares at a strike of $1.05, increasing direct ownership by 2% to 706,474 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    2/11/26 9:00:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Innovation Officer Scanlan Sean F. exercised 53,500 shares at a strike of $0.72 and was granted 262,500 shares, increasing direct ownership by 85% to 689,599 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    1/23/26 9:30:05 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Treace John T. covered exercise/tax liability with 14,254 shares and was granted 250,000 shares, increasing direct ownership by 3% to 7,011,633 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    1/23/26 9:30:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    SEC Filings

    View All

    SEC Form 10-K filed by Treace Medical Concepts Inc.

    10-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

    2/27/26 7:14:20 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

    2/27/26 7:10:38 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.

    SCHEDULE 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    2/17/26 9:36:05 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Treace John T. bought $524,064 worth of shares (60,000 units at $8.73), increasing direct ownership by 0.89% to 6,796,190 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    3/4/25 6:30:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Treace John T. bought $265,630 worth of shares (50,000 units at $5.31), increasing direct ownership by 0.77% to 6,523,095 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    9/17/24 5:17:19 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Director Treace James T bought $501,035 worth of shares (84,000 units at $5.96), increasing direct ownership by 7% to 1,223,441 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    8/19/24 9:00:08 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Treace Medical Concepts Inc.

    SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/14/24 3:38:23 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

    SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/12/24 6:01:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Treace Medical Concepts Inc.

    SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/8/24 3:44:13 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Financials

    Live finance-specific insights

    View All

    Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

    PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025. Recent Highlights Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% compared to the prior year.Reported fourth quarter 2025 net loss of $(9.4) million and adjusted EBITDA of $6.2 million in the fourth quarter 2025. Reported full-year 2025 net loss of $(59.0) million c

    2/27/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

    PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask qu

    2/12/26 5:13:32 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

    PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results. Highlights: Preliminary revenue of $62.1 million to $62.5 million in the fourth quarter of 2025, an approximate 9% decrease at the midpoint over the same period in 2024.Preliminary revenue of $212.3 million to $212.7 million for the full-year 2025, an approximate 2% increase at the midpoint compared to the prior year and in-line with the previousl

    1/13/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Leadership Updates

    Live Leadership Updates

    View All

    Treace Appoints Guy Guglielmino as Chief Commercial Officer

    PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace's commercial efforts and play a pivotal role in driving the Company's next phase of rapid innovation, strategic product commercialization, and growth. "I am thrilled to welcome Guy to the Treace team," said John T. Treace, CEO, Founder and B

    12/2/24 4:15:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

    PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts.  "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou

    8/21/23 7:00:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer

    PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit

    7/12/23 4:15:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care